Ftse Mib
38.592,81
-0,48%
DAX
23.008,94
-1,87%
S&P 500
5.770,20
0,55%
NASDAQ
18.196,22
0,70%
Bitcoin
83.368,01
-3,23%
Pepperstone
Advertisement
Registration Strip Icon for monitor Monitora più quotazioni in tempo reale dalle principali borse, come Borsa Italiana, NASDAQ, NYSE, AMEX, Bovespa e altro ancora.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ argenx SE (ARGX) argenx SE (ARGX) Notizie

ARGX

argenx (ARGX)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:ARGX
DataOraFonteTitoloSimboloCompagnia
07/03/202512:05Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:ARGXargenx SE
07/03/202507:00GlobeNewswire Inc.argenx Highlights FcRn Leadership with Long-term Data and Transformational Patient Outcomes at the American Academy of Neurology 2025 Annual MeetingNASDAQ:ARGXargenx SE
27/02/202507:00GlobeNewswire Inc.argenx Reports Full Year 2024 Financial Results and Provides Fourth Quarter Business UpdateNASDAQ:ARGXargenx SE
25/02/202507:00GlobeNewswire Inc.argenx to Present at TD Cowen 45th Annual Healthcare ConferenceNASDAQ:ARGXargenx SE
20/02/202507:00GlobeNewswire Inc.argenx to Report Full Year 2024 Financial Results and Fourth Quarter Business Update on February 27, 2025NASDAQ:ARGXargenx SE
12/02/202515:16Edgar (US Regulatory)Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:ARGXargenx SE
13/01/202507:00GlobeNewswire Inc.argenx Highlights 2025 Strategic PrioritiesNASDAQ:ARGXargenx SE
06/01/202507:00GlobeNewswire Inc.argenx to Present at 43rd Annual J.P. Morgan Healthcare ConferenceNASDAQ:ARGXargenx SE
27/12/202407:00GlobeNewswire Inc.argenx Announces Approval of VYVDURA (efgartigimod alfa and hyaluronidase-qvfc) in Japan for Adults with Chronic Inflammatory Demyelinating PolyneuropathyNASDAQ:ARGXargenx SE
26/11/202407:00GlobeNewswire Inc.argenx to Present at Upcoming Investor ConferencesNASDAQ:ARGXargenx SE
20/11/202407:00GlobeNewswire Inc.argenx Advances Clinical Development of Efgartigimod SC in Idiopathic Inflammatory MyopathiesNASDAQ:ARGXargenx SE
11/11/202413:30GlobeNewswire Inc.argenx and Zai Lab Announce Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy in ChinaNASDAQ:ARGXargenx SE
11/11/202413:30Business WireZai Lab and argenx Announce Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in ChinaNASDAQ:ARGXargenx SE
05/11/202407:00GlobeNewswire Inc.argenx to Participate at Upcoming Investor ConferencesNASDAQ:ARGXargenx SE
31/10/202407:00GlobeNewswire Inc.argenx Reports Third Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:ARGXargenx SE
24/10/202407:00GlobeNewswire Inc.argenx to Report Third Quarter 2024 Financial Results and Business Update on October 31, 2024NASDAQ:ARGXargenx SE
15/10/202407:00GlobeNewswire Inc.argenx Highlights Data Showing Patient Impact Across Multiple Immunology Programs at 2024 American Association of Neuromuscular & Electrodiagnostic Medicine Annual Meeting and Myasthenia Gravis Foundation of America Scientific SessionsNASDAQ:ARGXargenx SE
19/09/202407:00GlobeNewswire Inc.argenx Announces Publication in The Lancet Neurology of Pivotal ADHERE Study Data in Chronic Inflammatory Demyelinating PolyneuropathyNASDAQ:ARGXargenx SE
25/07/202407:00GlobeNewswire Inc.argenx Reports Half Year 2024 Financial Results and Provides Second Quarter Business UpdateNASDAQ:ARGXargenx SE
18/07/202407:00GlobeNewswire Inc.argenx to Report Half Year 2024 Financial Results and Second Quarter Business Update on July 25, 2024NASDAQ:ARGXargenx SE
16/07/202406:30GlobeNewswire Inc.argenx and Zai Lab Announce Approval of Efgartigimod Alfa Injection (Subcutaneous Injection) for Generalized Myasthenia Gravis in ChinaNASDAQ:ARGXargenx SE
16/07/202406:15Business WireZai Lab and argenx Announce Approval of Efgartigimod Alfa Injection (Subcutaneous Injection) for Generalized Myasthenia Gravis in ChinaNASDAQ:ARGXargenx SE
25/06/202422:30GlobeNewswire Inc.argenx Highlights Breadth of Autoimmune Pipeline with New Multifocal Motor Neuropathy Data at 2024 Peripheral Nerve Society Annual MeetingNASDAQ:ARGXargenx SE
21/06/202422:50GlobeNewswire Inc.argenx Announces FDA Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating PolyneuropathyNASDAQ:ARGXargenx SE
17/06/202407:00GlobeNewswire Inc.argenx to unveil its ‘Vision 2030: Taking Breakthrough Science to 50,000 Patients’ during its Upcoming R&D Day on July 16, 2024NASDAQ:ARGXargenx SE
04/06/202407:00GlobeNewswire Inc.argenx to Present at Goldman Sachs 45th Annual Global Healthcare ConferenceNASDAQ:ARGXargenx SE
09/05/202407:00GlobeNewswire Inc.argenx Reports First Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:ARGXargenx SE
07/05/202423:30GlobeNewswire Inc.argenx announces results of Annual General Meeting of ShareholdersNASDAQ:ARGXargenx SE
07/05/202407:00GlobeNewswire Inc.argenx to Present at BofA Securities 2024 Health Care ConferenceNASDAQ:ARGXargenx SE
02/05/202407:00GlobeNewswire Inc.argenx to Report First Quarter 2024 Financial Results and Business Update on May 9, 2024NASDAQ:ARGXargenx SE
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:ARGX

La tua Cronologia

BIT
UCG
Unicredit
BIT
ISP
Intesa Sanpaolo
BIT
LDO
Leonardo
BIT
STLAM
Stellantis NV
BIT
ENI
Eni
BIT
ENEL
Enel
BIT
RACE
Ferrari NV
BIT
SFER
Salvatore Ferragamo
BIT
MONC
Moncler
BIT
AMP
Amplifon
BIT
CPR
Davide Campari
BIT
BMPS
Banca Monte Dei Paschi D...
BIT
BAMI
Banco BPM
BIT
TIT
Telecom Italia
BIT
STMMI
ST Microelectronics
BIT
BPE
Bper Banca
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network

Rimuovi gli annunci

Iscriviti per un'esperienza senza pubblicità

Nessuna pubblicità

Prova adesso

Conserva gli annunci